Cost–consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer.

Autor:	Jensen, Ivar S1 (AUTHOR), Hathway, Joanne1 (AUTHOR), Cyr, Philip1,2 (AUTHOR), Gauden, David3 (AUTHOR) D.Gauden@blueearthDx.com, Gardiner, Peter4 (AUTHOR)
Zdroj:	Journal of Market Access & Health Policy. Dec2020, Vol. 8 Issue 1, p1-8. 8p.
Databáze:	Business Source Ultimate
Externí odkaz: